REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug cocktail shows promise for tough blood cancers, but study halted early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo for tough leukemias hits snag: trial ends early
Disease control TerminatedThis phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC